Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity

Purpose: The compound quinazoline Q-Br, 3-(5-bromo-2-hydroxybenzylideneamino)-2-(5-bromo-2 hydroxyphenyl) 2,3-dihydroquinazoline-4(1H)-one (Q-Br) was evaluated for its antioxidant capacity and potential hepatoprotectivity against sub-chronic liver toxicity induced by thioacetamide in rats.Materials...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzy Salama (Author), Chin Siang Kue (Author), Haryanti Mohamad (Author), Fatima Omer (Author), Mohamed Yousif Ibrahim (Author), Mahmood Abdulla (Author), Hapipah Ali (Author), Abdalbasit Mariod (Author), Soher Nagi Jayash (Author)
Format: Book
Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_dd8d93c5a86d440c9b5ea84e521580d3
042 |a dc 
100 1 0 |a Suzy Salama  |e author 
700 1 0 |a Chin Siang Kue  |e author 
700 1 0 |a Haryanti Mohamad  |e author 
700 1 0 |a Fatima Omer  |e author 
700 1 0 |a Mohamed Yousif Ibrahim  |e author 
700 1 0 |a Mohamed Yousif Ibrahim  |e author 
700 1 0 |a Mahmood Abdulla  |e author 
700 1 0 |a Hapipah Ali  |e author 
700 1 0 |a Abdalbasit Mariod  |e author 
700 1 0 |a Abdalbasit Mariod  |e author 
700 1 0 |a Soher Nagi Jayash  |e author 
245 0 0 |a Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity 
260 |b Frontiers Media S.A.,   |c 2022-09-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.943340 
520 |a Purpose: The compound quinazoline Q-Br, 3-(5-bromo-2-hydroxybenzylideneamino)-2-(5-bromo-2 hydroxyphenyl) 2,3-dihydroquinazoline-4(1H)-one (Q-Br) was evaluated for its antioxidant capacity and potential hepatoprotectivity against sub-chronic liver toxicity induced by thioacetamide in rats.Materials and Methods: Rats were assigned into five groups; healthy (normal) and cirrhosis control groups were given 5% Tween 20 orally, the reference control group was given a Silymarin dose of 50 mg/kg, and low-dose Q-Br and high-dose Q-Br groups were given a daily dose of 25 mg/kg and 50 mg/g Q-Br, respectively. Liver status was detected via fluorescence imaging with intravenous injection of indocyanine green (ICG) and a plasma ICG clearance test. Liver malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were also tested. The degree of fibrosis was determined histologically by hematoxylin and eosin and Masson's Trichrome staining. The immunohistochemistry of liver tissue inhibitor of metalloproteinase (TIMP-1), matrix metalloproteinase (MMP-2), and alpha-smooth muscle actin (α-SMA) was performed.Results: Q-Br recorded mild antioxidant capacity, dose-dependent improvement in the liver status, and inhibition of oxidative stress compared to cirrhosis control. Histopathology notified a remarkable reduction in the degree of fibrosis. Immunohistochemistry revealed an obvious low expression of MMP-2 and α-SMA along with a higher expression of TIMP-1 in Q-Br- and Silymarin-treated livers.Conclusion: Q-Br treatment altered the course of toxicity induced by thioacetamide suggesting significant hepatoprotective potential of Q-Br treatment. 
546 |a EN 
690 |a quinazoline 
690 |a indocyanine green-imaging 
690 |a oxidative stress 
690 |a liver fibrosis 
690 |a liver toxicity 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.943340/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/dd8d93c5a86d440c9b5ea84e521580d3  |z Connect to this object online.